The Experts below are selected from a list of 1866 Experts worldwide ranked by ideXlab platform

Lagro-janssen A.l.m. - One of the best experts on this subject based on the ideXlab platform.

  • Assessing the effectiveness of topical betamethasone to treat chronic Chilblains: a randomised clinical trial in primary care
    'Royal College of General Practitioners', 2017
    Co-Authors: Souwer I.h., Bor J.h.j., Smits P., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 174834.pdf (publisher's version ) (Closed access)BACKGROUND: GPs prescribe topical corticosteroids to patients with chronic Chilblains despite poor evidence for their effectiveness. The authors of the current study therefore decided to assess the effectiveness of topical steroids in a primary care setting. AIM: To assess the effectiveness of topical application of betamethasone valerate 0.1% cream in patients with chronic Chilblains. DESIGN AND SETTING: A placebo-controlled, double-blind, crossover, randomised clinical trial in a Dutch primary care setting. METHOD: The study population consisted of 34 participants suffering from chronic Chilblains. Intervention was topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks compared with placebo. Primary outcome was the visual analogue scale on complaints (VOC). Secondary outcome was the visual analogue scale on disability (VOD). Both were assessed with a diary of daily scores on a 100 mm visual analogue scale. The authors took ambient temperatures into account, checked for a carry-over effect, performed additional analysis, and monitored adverse effects. RESULTS: On the primary outcome mean VOC, there was a difference of 0.56 mm (95% confidence interval [CI] = -2.88 to 3.99 mm) in favour of placebo (P = 0.744). On the secondary outcome mean VOD, there was a difference of 0.88 mm (95% CI = -2.22 to 3.98 mm) in favour of placebo (P = 0.567). This study found no carry-over effect and no adverse effects. CONCLUSION: In this study, topical betamethasone was not superior to placebo in the treatment of chronic Chilblains. Topical betamethasone should not be used for chronic Chilblains without new evidence

  • Phenotypic familial aggregation in chronic Chilblains
    'Oxford University Press (OUP)', 2016
    Co-Authors: Souwer I.h., Smaal D., Bor J.h., Knoers N., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 170812.pdf (publisher's version ) (Closed access)BACKGROUND: Our clinical observations and two earlier studies indicate familial clustering to be involved in chronic Chilblains. Demonstrating phenotypic familial aggregation is a next step to investigate the origin of familial clustering. OBJECTIVE: This study was initiated to assess evidence for phenotypic familial aggregation in chronic Chilblains. METHODS: Using a case-control family design in a primary care setting, we computed the familial relative risk of at least one episode of chronic Chilblains during life with 95% confidence intervals (CIs). The study population consisted of 192 relatives of 31 case probands (at least one confirmed episode of chronic Chilblains). The control population consisted of 178 relatives of 31 sex- and age-matched index controls (no history of chronic Chilblains). RESULTS: The familial relative risk of chronic Chilblains was 3.6 (95% CI 1.9-7.3). Additional sensitivity analysis shows similar figures. CONCLUSION: We demonstrate robust phenotypic familial aggregation in chronic Chilblains

  • Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial
    2016
    Co-Authors: Souwer I.h., Bor J.h., Smits P., Lagro-janssen A.l.m.
    Abstract:

    PURPOSE: Nifedipine is commonly prescribed for the treatment of Chilblains (pernio, perniosis) on the basis of observational studies and a single small, older clinical trial. We aimed to confirm the proposed superiority of oral nifedipine 60 mg per day over placebo for treatment of chronic Chilblains in primary care. METHODS: We performed a randomized, placebo-controlled, double-blind, crossover trial, closely following the design of the older trial. A total of 32 patients with chronic Chilblains were randomly assigned to nifedipine (30 mg controlled release twice a day) or placebo. The primary outcome was patient-reported complaints; the secondary outcome was patient-reported disability. Both were assessed from daily ratings on 100-mm visual analogue scales recorded in a diary. We took ambient temperatures into account and checked for a carry-over effect, and monitored for adverse effects. RESULTS: After 6 weeks of treatment, mean scores on the visual analogue scale on complaints showed a nonsignificant difference of 1.84 mm (95% CI, -6.67 to 2.99 mm) in favor of nifedipine (P = .44). Mean scores on the visual analogue scale on disability showed a nonsignificant difference of 0.56 mm (95% CI, -2.97 to 4.09 mm) in favor of placebo (P = .75). There was no carry-over effect of prior study treatment. Nifedipine was associated with significantly lower systolic blood pressure and a significantly higher incidence of edema. CONCLUSIONS: In our study, nifedipine was not superior to placebo for treating chronic Chilblains. These findings contrast with those of the older study and do not support routine use of nifedipine for this condition

  • Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial
    'Annals of Family Medicine', 2016
    Co-Authors: Souwer I.h., Bor J.h., Smits P., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 170809.pdf (publisher's version ) (Open Access)PURPOSE: Nifedipine is commonly prescribed for the treatment of Chilblains (pernio, perniosis) on the basis of observational studies and a single small, older clinical trial. We aimed to confirm the proposed superiority of oral nifedipine 60 mg per day over placebo for treatment of chronic Chilblains in primary care. METHODS: We performed a randomized, placebo-controlled, double-blind, crossover trial, closely following the design of the older trial. A total of 32 patients with chronic Chilblains were randomly assigned to nifedipine (30 mg controlled release twice a day) or placebo. The primary outcome was patient-reported complaints; the secondary outcome was patient-reported disability. Both were assessed from daily ratings on 100-mm visual analogue scales recorded in a diary. We took ambient temperatures into account and checked for a carry-over effect, and monitored for adverse effects. RESULTS: After 6 weeks of treatment, mean scores on the visual analogue scale on complaints showed a nonsignificant difference of 1.84 mm (95% CI, -6.67 to 2.99 mm) in favor of nifedipine (P = .44). Mean scores on the visual analogue scale on disability showed a nonsignificant difference of 0.56 mm (95% CI, -2.97 to 4.09 mm) in favor of placebo (P = .75). There was no carry-over effect of prior study treatment. Nifedipine was associated with significantly lower systolic blood pressure and a significantly higher incidence of edema. CONCLUSIONS: In our study, nifedipine was not superior to placebo for treating chronic Chilblains. These findings contrast with those of the older study and do not support routine use of nifedipine for this condition

  • Vitamin D3 is not effective in the treatment of chronic Chilblains.
    'Wiley', 2009
    Co-Authors: Souwer I.h., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 77172.pdf (publisher's version ) (Closed access)BACKGROUND: Chronic Chilblains is a common disease causing major restrictions in daily life, nevertheless little is known about effective treatment. In a literature search, we found thin evidence of three interventions: fluocinolone cream, nifedipine and vitamin D3. OBJECTIVE: We have conducted a study to assess the effect of oral administration of 2000 IU vitamin D3 per day on patients suffering from chronic Chilblains. METHODS: The study was based on a self-controlled design. The study population consisted of patients with a confirmed diagnosis. Outcome measurement was the change in severity of the complaints and disability. We checked for interference by temperature and other confounders. LIMITATIONS: The size of the cohort (n = 33) was a limitation. RESULTS: After correction for confounding factors, 19% of the subjects reported fewer complaints and 6% fewer disability, in both the placebo and vitamin D3 treatment groups. CONCLUSION: Oral administration of 2000 IU vitamin D3 per day is not better than placebo in the treatment of patients with chronic Chilblains

Michel D'incan - One of the best experts on this subject based on the ideXlab platform.

  • Recent outbreak of chilblain-like lesions is not directly related to SARS-CoV-2 infection.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020
    Co-Authors: Jacques Rouanet, E. Lang, F. Beltzung, B. Evrard, C. Henquell, I. Joulie, Michel D'incan
    Abstract:

    Throughout March and April 2020, dermatologists have observed an outbreak of Chilblains despite climatic conditions not conducive to their apparition. These lesions have occurred simultaneously to the COVID-19 epidemic, suggesting a relationship between their onset and SARS-CoV-2 infection. Here we describe a series of 10 patients presenting chilblain-like lesions in whom we have searched for evidence of SARS-CoV-2 infection.

V. Descamps - One of the best experts on this subject based on the ideXlab platform.

  • Negative tests for SARS-CoV-2 infection do not rule out its responsibility for Chilblains.
    The British journal of dermatology, 2020
    Co-Authors: G. Battesti, V. Descamps
    Abstract:

    We read with great interest the report of Le Cleach et al discussing Chilblains as a manifestation of COVID-19 pandemic. They reported 311 patients with acral lesions occurring during the COVID-19 lockdown in France. The most frequent clinical presentation of these acral lesions was typical Chilblains. Among the 150 patients with RT-PCR testing and/or serology, only 10 had confirmed COVID-19. They concluded that there is no evidence of SARS-CoV-2 infection in the large majority of patients with acral lesions. They hypothesized that the situation could be due to the media stating that Chilblains were caused by SARS-CoV-2 infection and leading to a higher rate of consultation or the lockdown leading to more inactivity and long periods at home barefoot on a cold floor.

Souwer I.h. - One of the best experts on this subject based on the ideXlab platform.

  • Assessing the effectiveness of topical betamethasone to treat chronic Chilblains: a randomised clinical trial in primary care
    'Royal College of General Practitioners', 2017
    Co-Authors: Souwer I.h., Bor J.h.j., Smits P., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 174834.pdf (publisher's version ) (Closed access)BACKGROUND: GPs prescribe topical corticosteroids to patients with chronic Chilblains despite poor evidence for their effectiveness. The authors of the current study therefore decided to assess the effectiveness of topical steroids in a primary care setting. AIM: To assess the effectiveness of topical application of betamethasone valerate 0.1% cream in patients with chronic Chilblains. DESIGN AND SETTING: A placebo-controlled, double-blind, crossover, randomised clinical trial in a Dutch primary care setting. METHOD: The study population consisted of 34 participants suffering from chronic Chilblains. Intervention was topical application of betamethasone valerate 0.1% cream twice a day for 6 weeks compared with placebo. Primary outcome was the visual analogue scale on complaints (VOC). Secondary outcome was the visual analogue scale on disability (VOD). Both were assessed with a diary of daily scores on a 100 mm visual analogue scale. The authors took ambient temperatures into account, checked for a carry-over effect, performed additional analysis, and monitored adverse effects. RESULTS: On the primary outcome mean VOC, there was a difference of 0.56 mm (95% confidence interval [CI] = -2.88 to 3.99 mm) in favour of placebo (P = 0.744). On the secondary outcome mean VOD, there was a difference of 0.88 mm (95% CI = -2.22 to 3.98 mm) in favour of placebo (P = 0.567). This study found no carry-over effect and no adverse effects. CONCLUSION: In this study, topical betamethasone was not superior to placebo in the treatment of chronic Chilblains. Topical betamethasone should not be used for chronic Chilblains without new evidence

  • Chilblains in general practice
    [S.l. : s.n.], 2017
    Co-Authors: Souwer I.h.
    Abstract:

    Contains fulltext : 176187.pdf (publisher's version ) (Open Access)For centuries, doctors have recognised patients with complaints of a cold-induced condition known as perniones or Chilblains but the backgrounds of the condition are largely unknown. In thesis we studied how patients are affected by chronic Chilblains, what they do and expect from their doctors, familial aggregation of the disease and the treatment of the condition.Radboud University, 3 juli 2017Promotores : Lagro-Janssen, A.L.M., Smits, P.151 p

  • Phenotypic familial aggregation in chronic Chilblains
    'Oxford University Press (OUP)', 2016
    Co-Authors: Souwer I.h., Smaal D., Bor J.h., Knoers N., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 170812.pdf (publisher's version ) (Closed access)BACKGROUND: Our clinical observations and two earlier studies indicate familial clustering to be involved in chronic Chilblains. Demonstrating phenotypic familial aggregation is a next step to investigate the origin of familial clustering. OBJECTIVE: This study was initiated to assess evidence for phenotypic familial aggregation in chronic Chilblains. METHODS: Using a case-control family design in a primary care setting, we computed the familial relative risk of at least one episode of chronic Chilblains during life with 95% confidence intervals (CIs). The study population consisted of 192 relatives of 31 case probands (at least one confirmed episode of chronic Chilblains). The control population consisted of 178 relatives of 31 sex- and age-matched index controls (no history of chronic Chilblains). RESULTS: The familial relative risk of chronic Chilblains was 3.6 (95% CI 1.9-7.3). Additional sensitivity analysis shows similar figures. CONCLUSION: We demonstrate robust phenotypic familial aggregation in chronic Chilblains

  • Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial
    2016
    Co-Authors: Souwer I.h., Bor J.h., Smits P., Lagro-janssen A.l.m.
    Abstract:

    PURPOSE: Nifedipine is commonly prescribed for the treatment of Chilblains (pernio, perniosis) on the basis of observational studies and a single small, older clinical trial. We aimed to confirm the proposed superiority of oral nifedipine 60 mg per day over placebo for treatment of chronic Chilblains in primary care. METHODS: We performed a randomized, placebo-controlled, double-blind, crossover trial, closely following the design of the older trial. A total of 32 patients with chronic Chilblains were randomly assigned to nifedipine (30 mg controlled release twice a day) or placebo. The primary outcome was patient-reported complaints; the secondary outcome was patient-reported disability. Both were assessed from daily ratings on 100-mm visual analogue scales recorded in a diary. We took ambient temperatures into account and checked for a carry-over effect, and monitored for adverse effects. RESULTS: After 6 weeks of treatment, mean scores on the visual analogue scale on complaints showed a nonsignificant difference of 1.84 mm (95% CI, -6.67 to 2.99 mm) in favor of nifedipine (P = .44). Mean scores on the visual analogue scale on disability showed a nonsignificant difference of 0.56 mm (95% CI, -2.97 to 4.09 mm) in favor of placebo (P = .75). There was no carry-over effect of prior study treatment. Nifedipine was associated with significantly lower systolic blood pressure and a significantly higher incidence of edema. CONCLUSIONS: In our study, nifedipine was not superior to placebo for treating chronic Chilblains. These findings contrast with those of the older study and do not support routine use of nifedipine for this condition

  • Nifedipine vs Placebo for Treatment of Chronic Chilblains: A Randomized Controlled Trial
    'Annals of Family Medicine', 2016
    Co-Authors: Souwer I.h., Bor J.h., Smits P., Lagro-janssen A.l.m.
    Abstract:

    Contains fulltext : 170809.pdf (publisher's version ) (Open Access)PURPOSE: Nifedipine is commonly prescribed for the treatment of Chilblains (pernio, perniosis) on the basis of observational studies and a single small, older clinical trial. We aimed to confirm the proposed superiority of oral nifedipine 60 mg per day over placebo for treatment of chronic Chilblains in primary care. METHODS: We performed a randomized, placebo-controlled, double-blind, crossover trial, closely following the design of the older trial. A total of 32 patients with chronic Chilblains were randomly assigned to nifedipine (30 mg controlled release twice a day) or placebo. The primary outcome was patient-reported complaints; the secondary outcome was patient-reported disability. Both were assessed from daily ratings on 100-mm visual analogue scales recorded in a diary. We took ambient temperatures into account and checked for a carry-over effect, and monitored for adverse effects. RESULTS: After 6 weeks of treatment, mean scores on the visual analogue scale on complaints showed a nonsignificant difference of 1.84 mm (95% CI, -6.67 to 2.99 mm) in favor of nifedipine (P = .44). Mean scores on the visual analogue scale on disability showed a nonsignificant difference of 0.56 mm (95% CI, -2.97 to 4.09 mm) in favor of placebo (P = .75). There was no carry-over effect of prior study treatment. Nifedipine was associated with significantly lower systolic blood pressure and a significantly higher incidence of edema. CONCLUSIONS: In our study, nifedipine was not superior to placebo for treating chronic Chilblains. These findings contrast with those of the older study and do not support routine use of nifedipine for this condition

Jacques Rouanet - One of the best experts on this subject based on the ideXlab platform.

  • Recent outbreak of chilblain-like lesions is not directly related to SARS-CoV-2 infection.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2020
    Co-Authors: Jacques Rouanet, E. Lang, F. Beltzung, B. Evrard, C. Henquell, I. Joulie, Michel D'incan
    Abstract:

    Throughout March and April 2020, dermatologists have observed an outbreak of Chilblains despite climatic conditions not conducive to their apparition. These lesions have occurred simultaneously to the COVID-19 epidemic, suggesting a relationship between their onset and SARS-CoV-2 infection. Here we describe a series of 10 patients presenting chilblain-like lesions in whom we have searched for evidence of SARS-CoV-2 infection.